Trial Profile
A Randomized, Single-blind, Placebo-controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN RSV Vaccine in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs MVA-BN RSV (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Bavarian Nordic
- 11 Feb 2020 Results investigating safety, reactogenicity and immunogenicity of MVA-BN-RSV Vaccine in Healthy Subjects, published in the Vaccine
- 23 Feb 2017 Six month follow-up data published in a Bavarian Nordic media release.
- 29 Sep 2016 Results published in Bavarian Nordic media release.